First Circuit Declines Unfair Business Practice Claim Dismissal

Some court decisions arrive wearing a tuxedo. Others show up in work boots, track mud across the lobby, and still manage to teach a master class in business litigation. The First Circuit’s decision in Conformis, Inc. v. Aetna, Inc. belongs in the second category. At issue was whether a medical device maker had pleaded enough to keep several business tort claims alive after an insurer changed its coverage policy and labeled customized knee implants “experimental and investigational.” The district court had dismissed the complaint. The First Circuit, however, was not ready to send the whole case to the legal graveyard.

Most importantly for business litigators and companies that live or die by marketplace reputation, the appellate court declined to let the unfair business practice claim stay dismissed. In plain English, the court said: not so fast. If some of the underlying wrongdoing claims plausibly survive, the Chapter 93A claim for unfair or deceptive trade practices may survive, too. That makes this ruling far more than a niche fight about knees, insurance, and policy bulletins. It is a useful roadmap for how the First Circuit looks at product disparagement, tortious interference, and Massachusetts unfair business practice claims at the motion-to-dismiss stage.

The Business Dispute Behind the Appeal

The case centered on Conformis, a medical device company that makes customized knee replacement systems. According to the complaint, the company’s implants were designed around a patient’s anatomy rather than pulled from the standard off-the-shelf menu. That is not exactly a fast-food combo meal. It is more like tailoring a suit, except the suit goes in your knee and the fitting appointment is significantly less glamorous.

Conformis alleged that Aetna had covered its knee replacement system for years and then changed course in 2018 through a revised medical policy. The new policy stated that customized total knee implants were considered experimental and investigational because their effectiveness had not been established. Conformis claimed that statement was false, damaging, and commercially harmful. It also alleged that the policy shift caused a drop in use of its system because surgeons and providers became wary of reimbursement problems.

That set up the lawsuit. Conformis asserted claims for product disparagement, tortious interference with contractual relations, tortious interference with advantageous relations, and unfair or deceptive trade practices under Massachusetts General Laws Chapter 93A. The district court dismissed the claims. On appeal, the First Circuit took a more selective approach. Instead of rubber-stamping the dismissal from top to bottom, it separated the sturdy allegations from the weak ones and concluded that some claims had enough muscle to keep going.

Why the First Circuit Would Not Let the Chapter 93A Claim Die

The headline point is simple: the First Circuit reversed dismissal of the Chapter 93A claim because the viability of that claim depended on whether certain underlying tort theories remained alive. Once the court concluded that the complaint plausibly alleged product disparagement and tortious interference with advantageous relations, the unfair business practice claim no longer looked like a legal ghost. It had a pulse.

That matters because Chapter 93A is Massachusetts’ heavy-hitter statute for unfair or deceptive acts or practices. It is often paired with common-law claims in business litigation because it can widen both the theory of wrongdoing and the potential remedies. But Chapter 93A is not a magic wand. Plaintiffs still need to plead conduct that falls within the accepted boundaries of unfairness or deception and show a causal connection to a loss of money or property. The First Circuit made clear that this claim rises or falls with the factual backbone supporting the alleged misconduct.

Product Disparagement Was Not Just a Fancy Complaint Label

One of the more interesting parts of the decision was the court’s treatment of the product disparagement claim. Aetna argued, among other things, that the challenged policy language did not specifically identify Conformis and that the statements were not sufficiently actionable. The First Circuit was not convinced that those objections ended the matter at the pleading stage.

The court reasoned that even though the policy referred to customized total knee implants more generally, the complaint plausibly alleged that the statement could be understood as targeting Conformis in practice. That is a big point for businesses facing broad market statements that do not name them in neon lights but still hit them squarely in the revenue line. A statement aimed at a category may still be “of and concerning” a specific company if the surrounding context makes that inference plausible.

The court also found it plausible that Aetna’s statement about effectiveness could be treated as factual enough to support a disparagement theory. In other words, this was not merely puffery or corporate throat-clearing. At least as pleaded, it could be understood as a real-world assertion about whether the product worked. If that assertion was false and published recklessly or knowingly, the claim deserved further proceedings rather than an early burial.

One Tortious Interference Claim Survived, One Did Not

The First Circuit did not hand Conformis a clean sweep. It upheld dismissal of the claim for tortious interference with contractual relations because the complaint did not provide enough detail about specific contracts and how those contracts were broken. That part of the ruling is a reminder that courts still expect plaintiffs to show the bones of an actual contract claim, not just wave vaguely in the direction of “lots of business relationships” and hope the rest will sort itself out.

But the claim for tortious interference with advantageous relations stood on better footing. Here, the complaint allegedly described ongoing and probable future business relationships with healthcare providers and a reasonable expectation of economic benefit. The First Circuit found those allegations plausible enough to survive dismissal. That distinction is important. If you cannot point to a specific contract breach, you may still have a viable claim if the defendant’s conduct allegedly wrecked business expectancies in a concrete and foreseeable way.

What the Ruling Says About Chapter 93A Pleading Standards

For lawyers, compliance teams, insurers, manufacturers, and anyone else unlucky enough to attend recurring litigation meetings, the ruling offers several lessons.

First, Chapter 93A claims are often only as strong as the factual allegations under them. Courts do not want decorative statutory claims hanging off a complaint like holiday lights in July. If the underlying conduct looks implausible or conclusory, the Chapter 93A claim may collapse with it. But when a plaintiff plausibly alleges conduct that could qualify as commercially unfair, unethical, oppressive, or unscrupulous, dismissal becomes much harder to justify.

Second, context matters. The First Circuit did not treat Aetna’s policy statement as an isolated sentence floating in a vacuum. It looked at the alleged history of coverage, the abrupt policy reversal, the alleged evidence Conformis had provided to challenge the policy, and the claimed marketplace harm that followed. That contextual approach is a warning to businesses that publish formal policy statements, coverage rules, or category-wide product assessments. If the market reasonably reads those statements as a strike against a specific competitor or supplier, a court may do the same.

Third, the decision reinforces a practical truth about motions to dismiss: they are screening devices, not final exams. The First Circuit was not deciding whether Conformis would ultimately win. It was deciding whether the complaint contained enough factual heft to justify discovery and further litigation. That is a lower hill to climb than proving liability, but it is still a hill. Conformis cleared it for some claims and stumbled on others.

Why This Decision Matters Beyond Medical Devices

It would be easy to shrug and file this under “interesting if you sell knee implants.” That would be a mistake. The case speaks to a wider commercial reality: businesses increasingly influence each other through public-facing policies, digital bulletins, eligibility criteria, internal standards that leak into the market, and risk classifications that look neutral on paper but hit specific companies in the face.

Consider software vendors marked “non-compliant” by a major platform, suppliers labeled “unsafe” by a distributor, or financial products categorized as “unsupported” by a market gatekeeper. In each setting, words can move money. When those words allegedly overstate, distort, or mischaracterize the truth, the fallout may go beyond bruised feelings. It can become a product disparagement problem, a business interference problem, and, in Massachusetts, a Chapter 93A problem.

The First Circuit’s approach also shows why plaintiffs often plead layered business claims. A company may not know at the start whether a court will find a statement defamatory, disparaging, interfering, deceptive, or all of the above. By analyzing each claim separately, the court preserved the ones that rested on sufficiently concrete allegations and trimmed the ones that lacked detail. That is exactly how motion-to-dismiss review is supposed to work: scalpel, not sledgehammer.

Practical Takeaways for Businesses and Litigators

• Be careful with broad policy language. A statement about an entire product category may still be read as targeting a specific company.
• Document the basis for public-facing classifications. If a company calls a product experimental, unsafe, ineffective, or ineligible, it should be ready to show why.
• Plead contracts with detail. If a claim depends on breach of specific agreements, general references to customer relationships may not be enough.
• Do not underestimate Chapter 93A. In Massachusetts business litigation, it remains a powerful companion claim when the alleged conduct crosses from hard competition into unfair practices.

The Bigger Legal Signal

The larger signal from the First Circuit is that courts are willing to take reputational and market-based harms seriously when the complaint ties them to concrete allegations. Commercial speech is not harmless just because it appears in a policy bulletin instead of a television ad. A classification decision published on a website can reshape provider behavior, consumer expectations, reimbursement decisions, and market confidence. The court understood that commercial reality, and that understanding explains why it refused to let the unfair business practice claim stay dismissed.

In the end, the ruling did not declare Conformis the winner or Aetna the villain in a black cape twirling a mustache. Courts rarely indulge that kind of theater, even when litigants might privately enjoy it. What the First Circuit did say is more useful: if a complaint plausibly alleges false and commercially damaging statements, plausible interference with business expectancies, and resulting financial loss, the case deserves to proceed. For Chapter 93A purposes, that is often enough to keep the courthouse doors open.

Experiences Related to the Topic: What These Cases Feel Like in Real Life

Cases like this are not just about citations, motions, and judges writing polished opinions that lawyers later quote with suspicious enthusiasm. On the ground, disputes over unfair business practices usually feel messy, slow, and deeply human. A manufacturer sees a new policy go live and suddenly starts getting nervous calls from providers asking whether reimbursement is still available. Sales teams, who usually prefer talking about growth instead of litigation holds, begin hearing the same phrase again and again: “We love the product, but we are worried about coverage.” That sentence alone can drain momentum from a business faster than a Friday afternoon budget meeting.

From the provider side, the experience is just as practical. Surgeons, clinics, and hospitals do not have infinite appetite for reimbursement roulette. Even when they believe a product works, uncertainty creates friction. Staff members wonder whether claims will be denied. Patients worry about surprise costs. Administrators ask whether a different product will avoid a payment battle. Nobody wakes up thinking, “Today I hope to become a footnote in a commercial disparagement case.” So behavior shifts. Not always because the product is worse, but because uncertainty is expensive.

For in-house lawyers, these moments are usually a test of discipline. The first instinct may be outrage: how could a public-facing policy say that? The better instinct is documentation. Gather the timeline. Save the policy versions. Preserve the studies, emails, provider feedback, and revenue data. Identify whether the statement is merely annoying or actually actionable. The difference between a complaint that survives and one that gets tossed often comes down to whether the facts are specific enough to show real-world harm rather than abstract corporate indignation.

Litigators know another truth here: motions to dismiss are emotional weather systems. A business that has spent months or years feeling damaged by a competitor, insurer, or market gatekeeper wants validation early. But pleading-stage wins are partial by design. A court may say one claim survives, one fails, and one depends on the first two. That can feel unsatisfying to clients who were hoping for a cinematic victory speech. Still, survival matters. It means the case moves from accusation to evidence. In many business disputes, that is the moment the real pressure begins.

There is also a broader lesson in the lived experience of these cases. Reputation in modern commerce is often mediated by policies, portals, databases, and coverage criteria rather than by old-fashioned newspaper ads or blunt public attacks. A company may be injured not by someone yelling, “This product is terrible!” but by a formal-looking online statement that quietly tells the market a product is unproven, unsupported, or outside the acceptable lane. The language may sound clinical. The effect can be commercial dynamite. That is why decisions like this matter. They reflect the world businesses actually operate in, where a few sentences on a website can change behavior across an entire market.

Conclusion

The First Circuit’s decision is a sharp reminder that unfair business practice claims do not automatically disappear just because a district court dismisses the first draft of a complaint. When the pleadings plausibly show false or damaging commercial statements, disrupted business relationships, and real economic loss, appellate courts may reopen the door. In Conformis v. Aetna, that door reopened for the Chapter 93A claim because the court concluded that key underlying theories were plausibly alleged. For companies operating in high-stakes markets, the lesson is simple: words in policies, bulletins, and classifications can carry legal consequences. And when those words allegedly distort the marketplace, courts may decide the fight is far from over.

SEO Tags